Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Metastatic Prostate Cancer
Join Sandy Srinivas, MD and Alexey Aleshin, MD, MBA from Stanford Cancer Institute as they present their expertise on a range of cases pertaining to metastatic prostate cancer.
Prostate cancer is the most commonly diagnosed cancer and second-leading cause of cancer death in men. Many therapeutic options exist for patients with metastatic prostate cancer. Clinicians need to be knowledgeable about all of the options to be able to effectively evaluate their appropriateness for each patient and discuss the possible risks and benefits with patients. Such knowledge allows for informed, shared decision making, which can enable patients to receive optimal care that maximizes their survival while taking into account their values and preferences.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Sandy Srinivas, MD
Stanford Cancer Institute
Alexey Aleshin, MD, MBA
Stanford Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00026928; Approval Number: 170001935
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-050-L01-P
- 1.00 CCM clock hours
- 1.00 ACPE contact hours
- 1.00 ANCC contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Following this activity, participants should be able to:
- Assess the criteria used to select appropriate treatment options for patients with metastatic prostate cancer.
- Contrast the risks and benefits of different treatment options and possible sequences of therapies for patients with metastatic prostate cancer.
- Discuss treatment options with patients to inform decision-making.